RT Journal Article
SR Electronic
T1 Mitigation and herd immunity strategy for COVID-19 is likely to fail
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.25.20043109
DO 10.1101/2020.03.25.20043109
A1 Barbara Adamik
A1 Marek Bawiec
A1 Viktor Bezborodov
A1 Wolfgang Bock
A1 Marcin Bodych
A1 Jan Pablo Burgard
A1 Thomas Götz
A1 Tyll Krueger
A1 Agata Migalska
A1 Barbara Pabjan
A1 Tomasz Ożański
A1 Ewaryst Rafajłowicz
A1 Wojciech Rafajłowicz
A1 Ewa Skubalska-Rafajłowicz
A1 Sara Ryfczyńska
A1 Ewa Szczurek
A1 Piotr Szymański
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.25.20043109.abstract
AB On the basis of a semi-realistic SIR microsimulation for Germany and Poland, we show that the R0 parameter interval for which the COVID-19 epidemic stays overcritical but below the capacity limit of the health care system to reach herd immunity is so narrow that a successful implementation of this strategy is likely to fail. Our microsimulation is based on official census data and involves household composition and age distribution as the main population structure variables. Outside household contacts are characterised by an out-reproduction number R* which is the only free parameter of the model. For a subcritical domain we compute the time till extinction and prevalence as a function of the initial number of infected individuals and R*. For the Polish city of Wrocław we also discuss the combined impact of testing coverage and contact reduction. For both countries we estimate R* for disease progression until 20th of March 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to thank the University of Science and Technology Wroclaw, the University of Wroclaw and the Medical University of Wroclaw for their support and assistance to the MOCOS group. We also thank the City of Wroclaw, Nokia Wroclaw, EY GDS Poland and MicroscopeIT for their support.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data we used is either open source or as the census data from the countries we used was provided from the state of Germany and Poland resp.